Efficacy of a First-in-Class Polymerase Theta Degrader in Preclinical Cancer Models
Discovery and Development of pan-KRAS Degraders for Cancer Therapy
Distinctive Roles for Small Molecule Inhibitors of Immune Checkpoint Proteins (LE072)
Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies
SMARCA2/4 degraders relieve the differentiation block in AML via changes in chromatin looping and accessibility
Paralogue selective p300 degraders induce synthetic lethality in pre-clinical models of CBP-deficient and p300-dependent malignancies
Identification and characterization of paralogue selective CBP degraders for potential use in cancer therapy
Development of novel anti-SIRPα/β dual antibody with single-agent phagocytosis activity
A novel CCR4 antagonist induces potent anti-tumor response through inhibition of Treg migration into the tumor microenvironment
Targeting the SWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies
Targeting CBM, A Tri Protein Signalling Hub, By Inhibition Of MALT1 For The Treatment Of B- Cell Lymphomas
A Highly Differentiated Small Molecule Immune Checkpoint Inhibitor Dually Targeting PD-L1 And A2AR For Cancer Therapy
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer
Discovery of potent and paralog selective PROTAC degraders of CBP or p300 proteins for the treatment of various cancers
Potent anti-tumor activity of a selective and orally bioavailable reversible covalent CDK12 inhibitor
Discovery of AUR-112, a novel MALT1 protease inhibitor for the treatment of B cell lymphomas
Identification of paralog selective degraders of SMARCA2 and SMARCA4 for treatment of various cancers
Targeting CBP/p300 – Inhibition vs. Degradation for Potent Anti-Tumor Efficacy
Targeting DDR1 Kinase to Address Tumor Dissemination, Immune Exclusion, and Therapeutic Resistance
Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax
A phase 1, open label, dose escalation, First-in-Human (FIH) study evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of AUR 103 in patients with relapsed advanced malignancies (BHARAT-1)
Generation of profound anti-tumor immunity by AUR109, a spectrum-selective kinase inhibitor, either as a single agent or in combination with immune checkpoint inhibitors
A highly differentiated PDL1-A2AR dual inhibitor for potential use in cancer therapy
Targeting CBP/p300 – Inhibition vs Degradation for Potent Anti-tumor Efficacy
Amino Acid inspired oral immune checkpoint antagonists for cancer therapy
Oral Immune Checkpoint Antagonist Dually Targeting TIGIT & PD-1 Pathways for Cancer Therapy
Characterization of the anti-tumor immune activation potential of AUR107, a novel small molecule p300/CBP bromodomain inhibitor
Orally Bioavailable CBP and p300 Selective Degraders for the Treatment of AR- and ER- dependent Cancers
Targeting cancer with selective CBP/p300 bromodomain inhibitors
First in class orally bioavailable BET BRD degraders
Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313
Potent anti-tumor activity of AUR102, a selective covalent inhibitor of CDK7
Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies | ACS Medicinal Chemistry Letters
Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase
Peptide and peptide-inspired checkpoint inhibitors: Protein fragments to cancer immunotherapy
PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
In silico designing of targeted protein degraders
Orally bioavailable SMARCA2 degraders with exceptional selectivity and potency
Evaluation of AU-18069, a novel small molecule CBP/p300 bromodomain inhibitor for the treatment of cancers
Novel, potent and orally bioavailable small molecule CD73 inhibitors for cancer immunotherapy
IRAK4 Modulators for Treatment of Hematologic Malignancies
Design, synthesis, and biological evaluation of phenyl thiazole-based AR-V7 degraders
Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action
Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer
Targeting SWI/SNF ATPases in enhancer-addicted human cancers
Discovery of orally bioavailable SMARCA2/4 dual degraders for treatment of acute myeloid leukemia
AUR103 an oral small molecule CD47 antagonist in combination with azacytidine and bortezomib exhibits potent anti-tumor activity in myeloma and leukemia models in vitro
PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras
Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations
